011000 — Gene One Life Science Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩186bn
- KR₩193bn
- KR₩40bn
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 17,385 | 90,432 | 108,209 | 45,851 | 10,068 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 9,576 | 8,401 | 9,413 | 10,579 | 7,572 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 36,596 | 108,760 | 134,633 | 73,063 | 34,573 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10,004 | 22,427 | 110,382 | 144,369 | 111,399 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 51,152 | 136,571 | 250,857 | 222,867 | 151,008 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22,653 | 36,705 | 34,759 | 33,836 | 22,867 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 27,092 | 38,062 | 44,350 | 41,395 | 39,518 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 24,060 | 98,509 | 206,507 | 181,471 | 111,489 |
Total Liabilities & Shareholders' Equity | 51,152 | 136,571 | 250,857 | 222,867 | 151,008 |
Total Common Shares Outstanding |